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Abstract Functional constipation is a common healthcare
problem among children worldwide and accounts for high
healthcare usage and costs. Functional constipation is a
clinical diagnosis; the evaluation primarily consists of a
thorough medical history and a complete physical exami-
nation. Additional investigations are not necessary in most
cases. Treatment consists of non-pharmacological and
pharmacological interventions. Non-pharmacological
interventions involve education and demystification, toilet
training (with a reward system), and a defecation diary.
Pharmacological treatment comprises three steps: disim-
paction, maintenance treatment, and weaning. The treat-
ment of first choice is oral laxatives, preferably
polyethylene glycol. When this is insufficient, other ther-
apeutic agents are available. This review discusses the
evaluation and management of functional constipation in
the pediatric population and provides a summary of drug
treatment options.
Key Points
Functional constipation in children is a commonly
occurring disorder. It is a clinical diagnosis based on
medical history and physical examination.
In the treatment of functional constipation, the
medication of first choice for both disimpaction and
maintenance treatment is polyethylene glycol.
Other therapeutic agents (e.g., stimulant laxatives or
lubricants) may be useful as additional or second-
line therapy if adequate treatment with oral laxatives
is insufficient.
1 Introduction
Functional constipation (FC) is a common pediatric
healthcare problem worldwide, with reported prevalences
ranging between 0.7 and 29.6 % and a mean female-to-
male ratio of 2.1:1 [1]. FC is characterized by infrequent
bowel movements, hard and/or large stools, painful defe-
cation, and fecal incontinence, and is often accompanied by
abdominal pain [2]. These symptoms can have a significant
impact on a child’s well-being and health-related quality of
life [3–9]. It is estimated that constipation in children
accounts for 3 % of visits to a general pediatrician and up
to 25 % of visits to a pediatric gastroenterologist in the
USA [10]. Furthermore, healthcare costs for children with
constipation are higher than those for control subjects,
mostly because of ambulatory care costs and, to a lesser
degree, costs related to hospitalizations and emergency
room visits [11]. Estimations of the economic burden
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caused by childhood FC vary between studies [12, 13]. In
the USA, the total additional costs for childhood consti-
pation have been estimated to be US$3.9 billion per year
[13]. Furthermore, the same study revealed that the mean
total unadjusted annual expenditure for children with
constipation was three times higher than that for children
without constipation (US$3430/year versus US$1099/year)
[13].
This review focuses on the current approach to man-
agement of FC in the pediatric population and provides
practical guidance, including a summary of drug treatment
options.
1.1 Definition
To define FC and other functional defecation disorders in
children, the Rome III criteria were defined by a group of
pediatric gastroenterology experts in 2006 [14]. The
Rome III criteria for FC in children differentiate between
children up to 4 years of age and children aged C4 years.
These criteria are listed in Table 1. In the spring of 2016,
the newly revised Rome IV criteria are expected to be
published.
FC not responding to optimal conventional treatment for
at least 3 months is defined as intractable constipation [15].
1.2 Pathophysiology
In approximately 95 % of children with constipation, no
organic cause can be identified [15]. These children suffer
from FC. In the remainder of cases, constipation has an
organic cause, such as a metabolic or endocrine disorder,
anorectal anomalies, neuromuscular diseases, or Hirsch-
sprung’s disease [16].
The pathophysiology of FC is still incompletely under-
stood but is likely to be multifactorial. One important eti-
ological factor, especially in young children, is withholding
behavior, frequently occurring after a negative experi-
ence—e.g., a hard, painful, and/or frightening bowel
movement [17]. Stool-withholding behavior can lead to
fecal impaction—the presence of a large fecal mass in
either the rectum or the abdomen. Moreover, fecal
impaction often causes overflow fecal incontinence, which
is involuntary loss of soft stools that pass an obstructing
fecal mass.
Psychosocial factors, such as major life events, may play
an important role in the pathophysiology of FC. Further-
more, behavioral disorders, such as autism spectrum dis-
orders and attention deficit/hyperactivity disorder, are
associated with a higher risk of childhood constipation [18,
19]. Lastly, factors such as socioeconomic status, educa-
tional level, and parental child-rearing attitudes have been
designated as influencing factors in the pathophysiology of
FC in children [1, 20].
2 Evaluation
Evaluation of childhood constipation primarily consists of
a thorough medical history and a complete physical
examination [15]. In most cases, additional investigations
are not necessary.
2.1 Medical History
The medical history should focus on the child’s bowel
habits. Questions should address the defecation frequency,
number of episodes and timing of fecal incontinence, stool
consistency, withholding behavior, and painful and/or hard
bowel movements (see Table 1). The Modified Bristol
Stool Form Scale for Children can be used to define stool
consistency [21]. A daily bowel diary can be useful to
gather more reliable information about a child’s bowel
habits, since recall of bowel habits has proven to be inac-
curate [22]. Furthermore, information has to be sought on
coexistence of abdominal pain, dietary history, changes in
appetite, the presence of nausea and/or vomiting, and other
accompanying symptoms. Alarm symptoms suggestive of
Table 1 Rome III criteria for functional constipation [14]
Age\4 yearsa Developmental age of C4 yearsb
1.\3 defecations per week
2. C1 episode of fecal incontinence per week after acquisition of toileting
skills
3. History of excessive stool retention
4. History of painful or hard bowel movements
5. Presence of a large fecal mass in the rectum
6. History of large diameter stools, which may obstruct the toilet
1.\3 defecations in the toilet per week
2. C1 episode of fecal incontinence per week
3. History of retentive posturing or excessive volitional stool
retention
4. History of painful or hard bowel movements
5. Presence of a large fecal mass in the rectum
6. History of large diameter stools, which may obstruct the toilet
a Must fulfill C2 criteria for C1 month prior to diagnosis
b Must fulfill C2 criteria at least once per week for C2 months prior to diagnosis, with insufficient criteria for diagnosis of irritable bowel
syndrome
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an organic cause include—but are not limited to—delayed
passage of meconium, a history of blood in the stools
without the presence of fissures, failure to thrive, and
severe abdominal distension [15].
Details about the onset of symptoms, duration of
symptoms, and precipitating factors can provide more
insight into the pathophysiology. The duration until pas-
sage of the first meconium, the presence of fissures during
infancy, and feeding-type-change-related defecation alter-
ations in the past may provide valuable insights. It is also
important to obtain information about the child’s age at
successful toilet training. Special attention to psychosocial
problems and life events is warranted. Often, the start of
symptoms coincides with life events such as the divorce of
parents or the birth of a younger sibling.
A detailed medication history should include the use and
efficacy of oral laxatives, enemas, and behavioral treat-
ment, and the use of other medication that may influence
bowel movements.
For an elaborate disquisition on possible underlying
organic causes and alarm symptoms, readers are referred to
the evidence-based recommendations published by the
North American Society for Pediatric Gastroenterology,
Hepatology, and Nutrition (NASPGHAN) and the Euro-
pean Society for Pediatric Gastroenterology, Hepatology,
and Nutrition (ESPGHAN) [15].
2.2 Physical Examination
Besides assessing weight and height, the physical exami-
nation primarily consists of abdominal examination,
inspection of the perianal region, examination of the lum-
bosacral region, and neurological examination.
Abdominal examination mainly focuses on detection
of a palpable fecal mass. During perianal inspection, the
physician checks for anatomic abnormalities, perianal
feces, fissures, scars, and erythema. Fissures may indi-
cate hard and/or large diameter stools. Digital rectal
examination provides valuable information on the pres-
ence of a rectal fecal mass, anorectal sensation, and
sphincter tone [15]. During examination of the lum-
bosacral region, inspection should focus on the presence
of a dimple, a tuft of hair, or a gluteal cleft deviation. A
lower limb neuromuscular examination provides infor-
mation on the neurological integrity of the lumbosacral
region.
A history of smearing feces or detection of fissures and
hematomas during physical examination should always
raise suspicion of sexual abuse. Since the physical exam-
ination findings of most pediatric sexual abuse victims are
within normal limits, special attention should be paid to
abnormal behavior during physical examination (e.g.,
sexual acting out, extreme fear) [23].
2.3 Laboratory Testing
Standard laboratory testing is not necessary in the workup
for FC [15].
2.4 Radiology
Radiological testing is not required to diagnose childhood
constipation [15].
2.4.1 Abdominal Radiography
Although it is still frequently used by many physicians, a
‘‘plain’’ abdominal X-ray is not the appropriate tool to
demonstrate constipation. Unsatisfactory sensitivity and
specificity rates, as well as low inter- and intra-observer
reliability, have been reported for the different scoring
systems (Barr, Leech, Blethyn) that are used to evaluate
these abdominal X-rays [15, 24].
2.4.2 Colonic Transit Time
The colonic transit time (CTT) can be determined to eval-
uate colonic motility. The most widely used method is the
marker test; this uses radiopaque markers, which are
ingested orally and visualized with an abdominal X-ray [24–
26]. Two other, less frequently used, methods to determine
the CTT are radionuclide scintigraphy and wireless motility
capsules [27]. There is no evidence for routine use of the
CTT in the diagnostic workup of FC [15]. An extremely
prolonged CTT ([100 h), does however, indicate a severe
form of constipation [26]. In situations in which the diag-
nosis is not clear, a colonic transit study may be useful to
discriminate between functional constipation and functional
nonretentive fecal incontinence, a disorder characterized by
fecal incontinence without signs of constipation [15, 25, 28].
2.5 Other Investigations
Other investigations, such as rectal ultrasonography, mag-
netic resonance imaging (MRI), rectal barostat, barium
enemas, anorectal manometry, colonic manometry, colonic
scintigraphy, and rectal/colonic biopsies, are sometimes
indicated but do not belong in the routine workup of con-
stipation and therefore go beyond the scope of this review.
3 Non-Pharmacological Treatment
3.1 Education
Education and demystification are the first steps in the non-
pharmacological treatment of FC [29]. Information on the
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prevalence, symptoms, initiating and perpetuating (risk)
factors, treatment options, and prognosis should be provided.
Children should be actively involved in this conversation if
allowed by their developmental age. A non-accusatory
approach of both physicians and parents is of key importance
[29]. Children may feel guilty or embarrassed, especially
about fecal incontinence episodes; it is therefore important to
explain the pathophysiology of overflow incontinence.
Childhood constipation is often a long-lasting problem,
which should be explained to both parents and patients.
3.2 Toilet Training, Reward System, and Defecation
Diary
Since the stasis of feces in the rectum can maintain con-
stipation, it is important to evacuate the rectum frequently.
In children with a developmental age of C4 years, this can
be established by introducing a toilet-training program.
Toilet training involves sitting on the toilet for 5 min after
each meal to actively try to defecate. By going to the toilet
after a meal, the patient takes advantage of the gastrocolic
reflex that increases colonic peristalsis upon distension of
the stomach, facilitating defecation.
The importanceof a relaxedpostureduringdefecation should
be explained. To ensure a relaxed posture, foot support (by
means of a footstool) is needed for children whose feet do not
touch the floor when they are sitting on the toilet. To motivate a
child for toilet training, a reward system can be introduced,
where small gifts (e.g., stickers) are earned for completing toilet
trainings. A daily stool diary can help to objectify the bowel
pattern of children with FC. This diary also has a motivating
purpose and is a helpful tool to evaluate treatment.
3.3 Dietary Fiber, Fluid, and Physical Activity
It has been suggested that children with FC might benefit
from additional dietary fiber, extra fluid intake, and/or
increased physical activity. These three interventions are
discussed below.
3.3.1 Fiber
The normal dietary fiber requirements of children vary from
child to child and are age dependent; in children older than
2 years of age, aminimal dietary fiber intake of ‘‘ageplus 5 g’’
is usually recommended [30, 31]. A fiber intake below normal
limits is associated with FC [32]. Several randomized con-
trolled trials (RCTs) on the effect of dietary fiber in children
have been performed [33–37]. However, these studies have
used different definitions and outcomemeasures, and a recent
systematic review applying Grading of Recommendations
Assessment, Development and Evaluation (GRADE) has
shown the overall quality of the evidence to be low [38].
Therefore, normal fiber intake is recommended, but current
evidence does not support the use of extra fiber supplements in
childrenwith FCwith a sufficient dietary fiber intake [15, 38].
3.3.2 Fluid
As with fiber, normal fluid requirements vary from child to
child [39]. One study regarding extra fluid intake in chil-
dren with FC showed insufficient evidence of an advanta-
geous effect on FC symptoms [15, 40]. Therefore, extra
fluid intake in children with FC who already have a normal
fluid intake is not recommended [15].
3.3.3 Physical Activity
A large prospective birth-cohort study demonstrated that
physical activity is associated with a decreased risk of
having FC at the preschool stage [41]. However, no RCTs
on the effect of increased physical activity on FC in chil-
dren have been performed [15].
3.4 Behavioral Therapy
Behavioral problems occur in approximately one third of
patients with FC [42, 43]. This has led to the idea that
behavioral therapy might be a therapeutic option in these
children. However, in an RCT, behavioral therapy had no
advantage over conventional treatment with laxatives in
treating childhood constipation [15, 44]. Nevertheless,
when behavioral problems are present, behavioral therapy
or referral to mental health services, in addition to laxative
treatment, should be considered [44].
3.5 Biofeedback Training
Approximately 50 % of children with FC have abnormal
defecation dynamics [25]. Biofeedback training employs
reinforcing stimuli and thereby aims to achieve a recogniz-
able sensation with an appropriate response in children with
FC. The long-term goal is to teach children to recognize the
sensation by themselves. Several RCTs have assessed the
effect of biofeedback training on FC in children. However,
there were significant methodological differences between
these studies, which makes it difficult to compare them, and
the current evidence does not support the use of biofeedback
training for the treatment of childhood constipation [15, 45].
4 Pharmacological Treatment
Pharmacological treatment for FC consists of treatment
with laxatives and involves three steps: disimpaction,
maintenance treatment, and, eventually, weaning. The
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pharmacological treatment options will be discussed below
and are summarized in Table 2, including recommended
dosages. A treatment algorithm is provided in Fig. 1.
4.1 Principles of Pharmacological Treatment
4.1.1 Disimpaction
Fecal impaction, defined as the presence of a large fecal
mass in the rectum or abdomen, occurs in approximately
50 % of children with FC [25, 46]. Removal of this fecal
mass (disimpaction) is recommended prior to initiation of
maintenance treatment in order to increase treatment
success [47]. Pharmacological options for disimpaction
consist of rectally administered enemas or temporary high-
dose oral polyethylene glycol (PEG; 1–1.5 g/kg/day) for
3–6 days (with a maximum of 6 days) [48–50]. One study
has compared high-dose PEG and sodium docusate enemas
and found these to be equally effective for disimpaction
[48]. In comparison with enemas, high-dose PEG is asso-
ciated with a higher frequency of fecal incontinence during
treatment; however, PEG is recommended as the first
choice for disimpaction since it can be administered orally
and hence is less invasive [15].
4.1.2 Maintenance
After successful disimpaction, maintenance therapy should
be initiated to prevent re-accumulation of feces [47]. The
aim of maintenance treatment is to soften the stools, which
facilitates easy and frequent defecation. Several laxatives
(oral and rectal), as well as stool softeners, are available for
maintenance treatment. Again, PEG is the oral laxative of
first choice, in a dosage of 0.2–0.8 g/kg/day. Other thera-
peutic options are discussed below. Depending on the
severity of the symptoms, the effect of treatment should be
evaluated 1–2 weeks after initiation of treatment. Mainte-
nance treatment should be continued for at least 2 months,
and FC symptoms should be resolved for at least 1 month
before weaning is initiated. It is recommended that symp-
toms are evaluated again 2 months after cessation of
treatment, to prevent or detect relapses.
4.1.3 Weaning
Approximately 50 % of children with FC on maintenance
treatment can stop using their medication within 6–12
months after initiation of treatment [51]. Maintenance
medication should be gradually reduced, rather than
abruptly discontinued, in order to prevent a relapse [52].
Weaning can be considered when symptoms are stable
under maintenance treatment, which means that children
have a defecation frequency of C3 times per week and do
not fulfill any other Rome III criteria.
4.2 Osmotic Laxatives
Osmotic laxatives are the first step in the pharmacological
treatment of FC. They are poorly absorbed by the intestinal
wall, which leads to intraluminal accumulation of hyper-
osmolar particles. This stimulates retention of water in the
intestinal lumen, softening the stools and increasing peri-
stalsis through intestinal distension. Furthermore, some
osmotic laxatives increase peristalsis through a decrease in
intraluminal pH [53]. The most frequently used osmotic
laxatives are discussed below.




PEG 3350/4000 Maintenance: 0.2–0.8 g/kg/day in 1–2 doses
Fecal disimpaction: 1–1.5 g/kg/day
(maximum 6 days)
Lactulose 7 months–18 years: 1–2 g/kg/day in
1–2 doses
Lactitol 1–6 years: 0.5–1 g/kg/day in 2–3 doses
6–12 years: 10–30 g/day in 2–3 doses
12–18 years: 20–60 g/day in 2–3 doses
Bisacodyl 3–10 years: 5 mg/day in 1 dose (at night)
[10 years: 5–10 mg/day in 1 dose (at night)
Senna 2–6 years: 2.5–5 mg/day in 1–2 doses
6–12 years: 7.5–10 mg/day in 1–2 doses
[12 years: 15–20 mg/day in 1–2 doses
Sodium
picosulfate
1 month–4 years: 2.5–10 mg/day in 1 dose
4 to 18 years: 2.5–20 mg/day in 1 dose
Magnesium
hydroxide
2–5 years: 0.4–1.2 g/day in 1 or more doses
6–11 years: 1.2–2.4 g/day in 1 or more doses
12–18 years: 2.4–4.8 g/day in 1 or more doses
Rectal laxatives/enemas
Bisacodyl 2–10 years: 5 mg/day in 1 dose
[10 years: 5–10 mg/day in 1 dose
Sodium lauryl
sulfoacetate
1 month–1 year: 2.5 mL/dose (=0.5 enema)
1–18 years: 5 mL/dose (=1 enema)
Sodium docusate \6 years: 60 mL
[6 years: 120 mL





Oral: 3–18 years: 1–3 mL/kg/day in 1 or
more doses (maximum 90 mL/day)
Rectal: 2–11 years: 30–60 mL/day in
1 dose;[11 years: 60–150 mL/day in
1 dose
PEG polyethylene glycol
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Fig. 1 Flowchart of evaluation
and management of functional
constipation in children.
1Ensure adequate fiber and fluid
intake. 2Polyethylene glycol
(PEG) is recommended as the
first choice for disimpaction.
3Medications and dosages can
be found in Table 2. 4PEG is
recommended as the first choice
for maintenance treatment. 5The
first evaluation should be
scheduled after 2 weeks
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4.2.1 Polyethylene Glycol
PEG (or macrogol) is the first-choice osmotic laxative in
children with FC. It is a linear polymer, in which water
molecules are retained by means of hydrogen connections,
causing an intraluminal fluid volume increase. It is not
metabolized and is minimally (\1 %) absorbed in the
intestine [54]. Different types of PEG have been devel-
oped—PEG 3350 and PEG 4000, with molecular weights
of 3.350 and 4.000 g/mol, respectively. To minimize the
risk of disturbing the electrolyte balance by osmosis, a
combination of PEG with electrolytes can be used, which is
iso-osmotic instead of hypo-osmotic. PEG has been proven
to be more effective in increasing stool frequency (C3
times per week) than placebo, lactulose, and magnesium
hydroxide in the treatment of constipation [53, 55–57]. The
use of PEG is effective and safe, even in young children
(aged\2 years) [57–62]. Therefore, PEG is the osmotic
laxative of first choice in children with FC. The effect of
PEG usually occurs within 1–2 days; when fecal impaction
is being treated, this effect might be delayed and may take
up to 3 days. Side effects include fecal incontinence
(especially during disimpaction), flatulence, abdominal
pain, nausea, and abdominal bloating. In patients predis-
posed to water and electrolyte balance disturbances (pa-
tients with impaired hepatic or renal function, or patients
taking diuretics), laboratory electrolyte checks should be
considered.
4.2.2 Lactulose and Lactitol
Lactulose and lactitol are synthetic derivatives of lactose.
These hyperosmolar agents are not hydrolyzed by digestive
enzymes in the small intestine and are, for that reason,
poorly absorbed by the intestinal mucosa. In the colon,
these disaccharides are fermented into hyperosmolar low
molecular weight acids by intraluminal bacteria [63]. This
results in intraluminal water retention and a decrease in
intraluminal pH, which induces an increase in colonic
peristalsis. The bacterial fermentation of these agents also
leads to formation of gas, which induces additional
intestinal distension and increases peristalsis. The effect of
lactulose and lactitol is usually observed within a number
of days. Side effects of lactulose and lactitol are usually
mild and include flatulence, abdominal pain, and abdomi-
nal bloating. Chronic use can lead to electrolyte balance
disturbances.
Although lactulose is often prescribed to children with
FC, evidence supporting the use of lactulose in clinical
practice is scarce. Moreover, lactulose has been demon-
strated to be less effective than liquid paraffin or PEG in
outcomes of stool frequency per week, consistency, relief
of abdominal pain, and need for additional medication [53,
55]. No statistically significant difference in treatment
success between lactulose and lactitol, lactulose and senna,
or lactulose and dietary fiber has been found [53]. Since
lactulose is considered to be safe for all ages, it is rec-
ommended in case PEG is not available.
4.2.3 Magnesium Hydroxide (Milk of Magnesia)
The antacid magnesium hydroxide (also referred to as
‘‘milk of magnesia’’ in its suspension form) and other
magnesium salts (e.g., magnesium sulfate and magnesium
citrate) have a laxative effect. This effect is considered to
derive from the osmotic gradient that is caused by these
poorly absorbed hyperosmolar agents. The effect of mag-
nesium hydroxide occurs after 2–8 h, whereas the effect of
magnesium sulfate occurs after 1–3 h. When the effect of
PEG on stool frequency per week was compared with that
of magnesium hydroxide in children with FC, a statistically
significant result was found, favoring PEG [53]. Side
effects include diarrhea, hypotension, weakness, and
lethargy. Severe renal impairment is a contraindication for
the use of magnesium hydroxide.
4.3 Stimulant Laxatives
If osmotic laxatives alone prove to be insufficient in the
treatment of pediatric patients with FC, stimulant laxatives
can be considered as additional or second-line treatment.
Stimulant laxatives act directly on the intestinal mucosa,
stimulating intestinal motility and/or increasing water and
electrolyte secretion. Diphenylmethanes and anthraqui-
nones are stimulant laxatives and are often used in the
treatment of FC in children, although literature to support
these treatments are lacking [63–65]. Even though
abdominal pain is a common side effect, stimulant laxa-
tives are often well tolerated. They are considered to be
safe and effective, and can be used in the treatment of FC
in children [66].
4.3.1 Diphenylmethanes
Diphenylmethanes include bisacodyl and sodium picosul-
fate—both non-absorbable agents. In the colon, diphenyl-
methanes are hydrolyzed to their active metabolites, which
exert a local prokinetic effect and stimulate intestinal
secretion [63]. Bisacodyl can be administered orally or
rectally. The laxative effect of ingested bisacodyl generally
occurs within 6–8 h; therefore it is recommended to
administer oral bisacodyl ante noctum. Rectally adminis-
tered bisacodyl induces a fast effect (sometimes within
30–60 min). Sodium picosulfate is available only as an oral
drug; the time for it to take effect is comparable to that of
orally ingested bisacodyl. The most common side effects
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are abdominal pain, nausea, and diarrhea. Rectal adminis-
tration of bisacodyl is contraindicated in children with
proctitis or anal fissures.
4.3.2 Anthraquinones
Senna contains a variety of anthraquinones and is metab-
olized into its pharmacologically active metabolite by
intestinal bacteria [63]. This metabolite stimulates colonic
motility and secretion of water and electrolytes, while it
inhibits absorption of water and electrolytes from the
colon. Side effects include abdominal pain, nausea, diar-
rhea, and flatulence. In young children, senna may poten-
tially cause severe diaper rash, blisters, and skin sloughing,
and it should therefore only be used in children
aged C1 year [67].
4.4 Lubricants
Lubricants are a class of laxatives that mainly soften or
lubricate stools.
4.4.1 Mineral Oil
Mineral oil (or liquid paraffin) is a derivative of petroleum.
It is not absorbed by the intestines, and it functions as a
lubricant. Mineral oil may also exert an osmotic effect
when it is converted to fatty acids [65, 68]. It can be
administered orally or rectally; the laxative effect generally
occurs within 1–2 days for both administration routes.
There have been a few low-quality trials comparing
mineral oil with oral laxatives in the treatment of childhood
constipation. Two studies compared mineral oil with lac-
tulose [69, 70]; a meta-analysis revealed a significant
improvement in stool frequency, although the quality of the
evidence was low [53]. Liquid paraffin was also compared
with PEG, which revealed no significant difference in
treatment response (defined as an increase in bowel
movements and a decrease in fecal incontinence frequency)
between both groups [71]. In comparison with senna, liquid
paraffin was shown to significantly improve the defecation
frequency and fecal incontinence episodes; however, the
evidence was of low quality [72].
Liquid paraffin is considered to be safe and efficacious
in the treatment of FC in children [68]. However, liquid
paraffin may leak out of the anus, causing irritation or
itching of the skin, and it may stain clothing or furniture.
Liquid paraffin can reduce absorption of fat-soluble vita-
mins (A, D, E, and K), although this is rarely clinically
relevant. There have been incidental reports of severe side
effects, such as granulomata following absorption, and
lipoid pneumonia following aspiration [68, 73, 74]. The
Committee on Safety of Medicines has therefore recom-
mended that liquid paraffin should not be administered to
children under 3 years of age [68].
4.4.2 Docusate
Sodium docusate is a mainly rectally administered thera-
peutic agent, although oral products exist. The surface-
active properties of sodium docusate instigate retention of
water in the stools, which renders its lubricating effect [63,
75]. There is no evidence that docusate is effective in
pediatric patients with FC. Side effects are seldom reported
but include diarrhea and rectal discomfort.
4.5 Enemas
Enemas are rectally administered fluids, which contain
chemically active agents that influence gut motility, agents
that exert an osmotic effect, or a combination of both. The
effect of enemas is usually seen within minutes after
administration. A number of different enemas are used in
the treatment of FC in children. Sodium lauryl sulfoacetate
brings about a redistribution of the water that is bound to
hard feces and exerts a softening effect on feces. This
enema does not have an osmotic effect and is usually used
in infants. Sodium docusate enemas contain docusate,
sometimes with added sorbitol, a hyperosmolar agent that
attracts water. Sodium phosphate enemas contain a strong
hyperosmolar phosphate solution. PEG and enemas have
been proven to be equally effective in achieving disim-
paction, but PEG is recommended because of the more
invasive nature of enemas [15, 48]. Evidence does not
support addition of enemas to chronic use of laxatives in
children with constipation [15]. The most common side
effects of enemas are abdominal pain and anorectal dis-
comfort. Sodium phosphate enemas are contraindicated if
Hirschsprung’s disease is suspected, since they have the
potential to induce hyperphosphatemia.
4.6 Rectal Irrigation
Transanal rectal/colonic irrigation is a procedure where
water is infused into the rectum and/or colon to mechani-
cally clean out the intestine. Rectal irrigation was shown to
be effective in the management of fecal incontinence due
to constipation in children with neurogenic defecation
disorders (e.g., spina bifida or Hirschsprung’s disease) or
anorectal malformations [76–82]. However, data on the
effectiveness of transanal irritation in children with FC are
scarce [83]. Irrigations are usually performed with a vol-
ume of 10–20 mL/kg of water, with the frequency
depending on the patient’s response [76, 83].
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4.7 Novel Therapies (Lubiprostone, Linaclotide,
and Prucalopride)
Lubiprostone, linaclotide, and prucalopride are relatively
new drugs, which have been found to be effective in con-
stipated adults [84]. However, data on the efficacy of these
agents in the treatment of childhood constipation are scarce
or lacking.
Lubiprostone and linaclotide both promote secretion of
chloride-rich fluid in the intestine, thereby softening stools
and enhancing stool volume. Lubiprostone is a pros-
taglandin E1 derivative, which activates chloride channel
subtype 2 (ClC-2). A pilot study has been conducted,
evaluating the effect of lubiprostone in childhood consti-
pation; the results suggested that lubiprostone significantly
increases bowel movements and is well tolerated in chil-
dren and adolescents with FC [85]. Side effects include
nausea, vomiting, diarrhea, and abdominal pain [85].
Linaclotide is a synthetic peptide, which activates the
luminal guanylin receptor on enterocytes and thereby
promotes fluid secretion. To date, no randomized studies
on the efficacy of linaclotide have been published in chil-
dren. In adults, the most frequently reported adverse effect
of linaclotide is diarrhea [84, 86, 87].
Prucalopride is a selective, high-affinity 5-hydrox-
ytryptamine (serotonin) receptor 4 agonist, which enhances
motility in the gastrointestinal tract [88]. In an open-label,
non-controlled, 8-week study, treatment with prucalopride
had a favorable effect on stool frequency, stool consis-
tency, and fecal incontinence frequency [89]. However, in
a recently published European multicenter double-blind
RCT in children with constipation, prucalopride was no
more effective than placebo in increasing the stool fre-
quency or decreasing the fecal incontinence frequency.
Reported adverse effects include headache, nausea,
abdominal pain, and diarrhea [88].
4.8 Probiotics
Over the past decades, advances in culture-independent
techniques have led to the discovery that in and on the
human body, bacterial cells outnumber human cells by an
estimated factor of ten [90–92]. The detection of species
that could not be detected previously by culture-based
methods has initiated the uncovering of the human
microbiome, demonstrating novel concepts that could sig-
nificantly alter the way we treat disease and promote health
in the future [93]. The exact relationship between gut
microbiota alterations and FC is still incompletely under-
stood. However, by altering the gut microbiota, probiotics
are able to influence colonic motility. Bacterial production
of short-chain fatty acids lowers the pH in the colon, which
enhances colonic peristalsis and thereby decreases the CTT
[94]. Studies on the use of probiotics have been conducted
in children, but, to date, there is insufficient evidence to
support the use of probiotics in the treatment of childhood
constipation [38, 95].
5 Prognosis and Follow-Up
A large proportion of children with FC can be treated
effectively with the therapeutic agents that are currently
available. Pijpers et al. [51] conducted a systematic review
of prospective follow-up studies on the prognosis of FC in
the hospital setting (pediatrics and pediatric gastroen-
terology). On the basis of these largely heterogeneous
studies, they concluded that within 6–12 months, approx-
imately 50 % of the children with FC had recovered and
were taken off laxatives. An additional 10 % of patients
were free of symptoms on medication, and another 40 %
would still be symptomatic despite the use of laxatives
[51]. After a follow-up period of 5–10 years,
56.0 % ± 11.3 % of the children had recovered and were
no longer taking laxatives. In tertiary care centers, these
numbers are similar: 50 % of children referred to a pedi-
atric gastroenterologist have recovered after 5 years, with
the vast majority of patients no longer taking laxatives, and
after 10 years, 80 % of children have recovered [15].
However, in the remainder of the children, symptoms may
persist into adolescence or even adulthood, despite laxative
treatment [96–98].
Early adequate therapeutic intervention is of key
importance in the management of childhood FC, since a
delay between the onset of symptoms and the first pre-
sentation at the department of pediatric gastroenterology is
negatively related to recovery [98].
In children with severe intractable constipation that is
unresponsive to intensive pharmacological treatment,
referral to a specialized pediatric gastroenterology and
motility center for further evaluation is recommended. In
these children, surgical management may be indicated as a
treatment of last resort [15, 99].
6 Conclusions
Childhood constipation is a common healthcare problem
worldwide. The diagnosis is based on the history and a
physical examination, in accordance with the Rome III
criteria. Additional investigations are required only in sit-
uations in which the diagnosis is not clear, and in order to
rule out an underlying disease. Non-pharmacological
management involves education, demystification, a toilet
program with a reward system, and a daily bowel diary.
Pharmacological treatment with laxatives consists of
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disimpaction, maintenance treatment, and eventually
weaning off medication. PEG is the laxative of first choice
for both disimpaction (high-dose: 1–1.5 g/kg/day) and
maintenance treatment (0.2–0.8 g/kg/day). If PEG is not
available or is poorly tolerated, lactulose is recommended.
Stimulant laxatives (bisacodyl, senna, sodium picosulfate),
magnesium hydroxide, and/or mineral oil may be consid-
ered as second-line or additional treatment if treatment
with osmotic laxatives is insufficient. Maintenance treat-
ment should be continued for at least 2 months, and FC
symptoms should be resolved for at least 1 month before a
gradually reduction of the medication. The long-term
prognosis is moderate even if early adequate therapeutic
interventions are applied.
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